Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
Negin Misaghian(East Carolina University), James A. McCubrey(East Carolina University), Franca Stivala(University of Catania), Giovanni Ligresti(Boston University), Massimo Libra(University of Catania), Michèle Milella(National Cancer Institute), Melchiorre Cervello(Foundation for Biomedical Research), Ferdinando Nicoletti(University of Catania), A M Martelli(Istituto Nazionale di Fisica Nucleare, Sezione di Bologna), F. E. Bertrand(Oak Ridge National Laboratory), Agostino Tafuri(Azienda Ospedaliera Sant'Andrea), Linda S. Steelman(East Carolina University), Jörg Bäsecke(University of Göttingen)
Cited by 187
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878